Jessica Meshman1, Pin-Chieh Wang1, Robert Chin1, Maie St John2, Elliot Abemayor2, Sunita Bhuta3, Allen M Chen4. 1. Departments of Radiation Oncology, University of California, Los Angeles, David Geffen School of Medicine. 2. Otolaryngology- Head and Neck Surgery, University of California, Los Angeles, David Geffen School of Medicine. 3. Pathology, University of California, Los Angeles, David Geffen School of Medicine. 4. Departments of Radiation Oncology, University of California, Los Angeles, David Geffen School of Medicine. Electronic address: achen5@kumc.edu.
Abstract
PURPOSE: To evaluate the prognostic significance of p16 expression among patients with squamous cell carcinoma of the larynx (LSCC) and hypopharynx (HSCC). METHODS: The medical records of all patients with locally advanced, non-metastatic LSCC/HSCC were reviewed. p16INK4A (p16) protein expression was evaluated on pathological specimens by immunohistochemistry (IHC), and the Kaplan-Meier method was used to estimate overall survival (OS) and locoregional control (LRC). In select cases, p16 expression was correlated to high-risk and low-risk HPV genotypes using in situ hybridization (ISH). RESULTS: Thirty-one patients (23 LSCC; 8 HSCC) were identified. Seventeen (54.8%) patients were p16 negative; 14 (45.2%) were p16-positive. The primary treatment modality was radiation therapy for 22 (71.0%) patients and surgery for 9 (29.0%). Nineteen (61.3%) patients were evaluated for high-risk HPV and low-risk HPV genotypes by IHC, of whom 2 (10.5%) patients were positive for high-risk HPV and 1 (5.3%) was positive for low-risk HPV. For high-risk HPV, the positive predictive value (PPV), sensitivity, and specificity of p16 was 20.0%, 100%, and 52.9%. There was no significant difference in the 2-year actuarial rates of OS (91% vs. 64%, p=0.34) or LRC (51% vs. 46%, p=0.69) between the p16-positive and p-16 negative patients. CONCLUSION: In this small cohort of 31 LSCC and HSCC patients, p16 was not a significant predictive of either LRC or OS. Furthermore, p16 was poorly correlated with HPV genotyping as identified by ISH.
PURPOSE: To evaluate the prognostic significance of p16 expression among patients with squamous cell carcinoma of the larynx (LSCC) and hypopharynx (HSCC). METHODS: The medical records of all patients with locally advanced, non-metastatic LSCC/HSCC were reviewed. p16INK4A (p16) protein expression was evaluated on pathological specimens by immunohistochemistry (IHC), and the Kaplan-Meier method was used to estimate overall survival (OS) and locoregional control (LRC). In select cases, p16 expression was correlated to high-risk and low-risk HPV genotypes using in situ hybridization (ISH). RESULTS: Thirty-one patients (23 LSCC; 8 HSCC) were identified. Seventeen (54.8%) patients were p16 negative; 14 (45.2%) were p16-positive. The primary treatment modality was radiation therapy for 22 (71.0%) patients and surgery for 9 (29.0%). Nineteen (61.3%) patients were evaluated for high-risk HPV and low-risk HPV genotypes by IHC, of whom 2 (10.5%) patients were positive for high-risk HPV and 1 (5.3%) was positive for low-risk HPV. For high-risk HPV, the positive predictive value (PPV), sensitivity, and specificity of p16 was 20.0%, 100%, and 52.9%. There was no significant difference in the 2-year actuarial rates of OS (91% vs. 64%, p=0.34) or LRC (51% vs. 46%, p=0.69) between the p16-positive and p-16 negative patients. CONCLUSION: In this small cohort of 31 LSCC and HSCC patients, p16 was not a significant predictive of either LRC or OS. Furthermore, p16 was poorly correlated with HPV genotyping as identified by ISH.
Authors: Alex K Bryant; Elena J Sojourner; Lucas K Vitzthum; Kaveh Zakeri; Hanjie Shen; Cammie Nguyen; James D Murphy; Joseph A Califano; Ezra E W Cohen; Loren K Mell Journal: J Natl Cancer Inst Date: 2018-12-01 Impact factor: 13.506
Authors: Roberto Gallus; Tarik Gheit; Dana Holzinger; Marco Petrillo; Davide Rizzo; Gianluigi Petrone; Francesco Miccichè; Gian Carlo Mattiucci; Damiano Arciuolo; Giampiero Capobianco; Giovanni Delogu; Vincenzo Valentini; Massimo Tommasino; Francesco Bussu Journal: Vaccines (Basel) Date: 2022-01-27
Authors: Nicholas Scott-Wittenborn; Gypsyamber D'Souza; Sakshi Tewari; Lisa Rooper; Tanya Troy; Virginia Drake; Elaine O Bigelow; Melina J Windon; William R Ryan; Patrick K Ha; Ana P Kiess; Brett Miles; William H Westra; Wojciech K Mydlarz; David W Eisele; Carole Fakhry Journal: Cancer Date: 2022-02-08 Impact factor: 6.921